Skip to content

Bedaquiline is now recommended as a core part of drug-resistant TB treatment, but price is a major concern to ensuring all who need treatment with bedaquiline receive it. The public has made significant investments in the development and introduction of bedaquiline, which should be reflected in the price of bedaquiline.

TAG’s “Reality Check” outlines the public’s investments in the development of bedaquiline and the publicly supported incentives from which Janssen, the drug’s sponsor and a subsidiary of Johnson & Johnson, has benefited. The “Reality Check” also dispels myths that have been circulated among members of the global TB community and used to justify pricing bedaquiline out of the reach of TB programs and patients.


Back To Top